Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) FCF Margin (2016 - 2025)

Historic FCF Margin for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to 1109.42%.

  • Pharma's FCF Margin fell 8606400.0% to 1109.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 508.68%, marking a year-over-year decrease of 851000.0%. This contributed to the annual value of 386.07% for FY2025, which is 107300.0% up from last year.
  • As of Q3 2025, Pharma's FCF Margin stood at 1109.42%, which was down 8606400.0% from 431.4% recorded in Q2 2025.
  • In the past 5 years, Pharma's FCF Margin registered a high of 183.39% during Q1 2024, and its lowest value of 4167.86% during Q3 2021.
  • In the last 5 years, Pharma's FCF Margin had a median value of 671.69% in 2022 and averaged 1092.77%.
  • Over the last 5 years, Pharma's FCF Margin had its largest YoY gain of 61320100bps in 2021, and its largest YoY loss of -19702600bps in 2021.
  • Quarter analysis of 5 years shows Pharma's FCF Margin stood at 1724.65% in 2021, then skyrocketed by 61bps to 671.69% in 2022, then fell by -21bps to 811.27% in 2023, then surged by 36bps to 522.96% in 2024, then plummeted by -112bps to 1109.42% in 2025.
  • Its FCF Margin was 1109.42% in Q3 2025, compared to 431.4% in Q2 2025 and 226.67% in Q1 2025.